Modalis Therapeutics
4883.TTSE GROWTHPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | ¥41m | ¥1m | ¥342m |
| Operating income | −¥2.2bn | −¥1.3bn | −¥2.4bn | −¥2.1bn | −¥1.2bn | — |
| Ordinary income | −¥2.1bn | −¥1.3bn | −¥2.4bn | −¥2.0bn | −¥1.2bn | −¥440m |
| Net income (owners) | −¥2.2bn | −¥1.3bn | −¥2.4bn | −¥2.7bn | −¥739m | −¥448m |
| Total assets | ¥3.0bn | ¥3.7bn | ¥2.0bn | ¥3.1bn | ¥6.1bn | ¥6.3bn |
| Net assets / equity | ¥2.8bn | ¥3.5bn | ¥1.4bn | ¥2.9bn | ¥5.5bn | ¥6.2bn |
| Operating cash flow | −¥2.1bn | −¥1.4bn | −¥2.3bn | −¥1.9bn | −¥747m | −¥377m |
| EPS (basic) | ¥-27.86 | ¥-28.57 | ¥-77.24 | ¥-92.85 | ¥-25.7 | ¥-17.02 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 2
| Period | Form | Figures |
|---|---|---|
| 2025-01-01 → 2025-12-31 | Annual | 172 figures · EDINET |
| 2025-01-01 → 2025-06-30 | Half-year | 62 figures · EDINET |
8 more reports are still being processed.